Year-end report 2011

The Board and President of Biolight AB (publ) herewith present its financial statement for the financial year 2011.

(For complete year-end report see attached file)

Biolight is a medical technology company offering products based on the biological effects of dynamic, monochromatic light. Biolight provides a patented system for effective, painless and safe treatment of primarily wounds and other inflammatory conditions. The method accelerates the body’s own healing process and supplements traditional treatment. The treatment is non-pharmaceutical and is applied externally. It prevents inflammatory injuries, contributes to enhanced quality of life, reduces recovery time after physical exertion, as well as reduces healing times and treatment costs.

Over the last couple of years, Biolight has mainly focused on two application areas: treatment of slow-healing wounds in medical and geriatric care and injuries in equestrian sports. The Biolight share is listed on the Nordic MTF (Nordic Growth Market AB).

• Net sales for the year were SEK 6,305 thousand (7,861).

• Net sales for the fourth quarter were SEK 1,258 thousand (1,511).

• Net operating loss for the year was SEK -13,147 thousand (-9,075).

• Net operating loss for the fourth quarter was SEK -4,188 thousand (-3,291).

• Loss per share was SEK -0.36 (-0.41), and SEK -0.36 (-0.41) after full dilution.

• New share issues were completed in March/April and November/December. They were oversubscribed, providing the Company with SEK 16.7 million before issue expenses.

Further information:

For further information, please contact Pär Olausson Lidö, President, tel: +46 8 753 70 89, or +46 702 15 01 11.

Biolight AB (publ) is a medical technology company offering solutions to care providers based on the Company’s patented method for using pulsating monochromatic light. The Company’s method reduces healing times and treatment costs. Over the last couple of years, Biolight has focused on a small number of application areas, primarily treatment of slow-healing wounds and injuries within equestrian sports. The Biolight share is listed on the Nordic MTF (Nordic Growth Market AB).